Feasibility · Solid tumors · Phase I–II heavy
Oncology — solid tumors trial feasibility, cited to its source.
Solid-tumor oncology is the most crowded area in clinical research, which makes site competition and patient overlap the dominant feasibility risks. A defensible read has to account not just for prevalence but for how many trials are already chasing the same biomarker-defined population.
Deterministic, re-runnable feasibility scoring.
What drives feasibility here
The questions that decide go or no-go.
- Site saturation: many sites are already running competing studies in the same tumor type, so raw site counts overstate available capacity.
- Biomarker eligibility narrows the addressable cohort sharply — cohort reachability matters more than crude incidence.
- Precedent matters for PTRS: prior approvals and late-phase outcomes in the tumor type and mechanism are strong priors.
- Geographic concentration of comprehensive cancer centers shapes country and site strategy.
Grounded in public data
For solid tumors, the verdict draws primarily on ClinicalTrials.gov, AACT, PubMed, FDA, Open Targets — every figure links back to its source record with a snapshot date, so your team and the sponsor can re-verify it. See the full data sources and compare other indications.
See a cited verdict for solid tumors.
Send us a protocol. We'll return a fully cited feasibility verdict you can trace, line by line, back to public data — yours to white-label, defend in a bid, or hand to a regulator.